TA Associates has successfully completed a voluntary public tender offer to acquire all outstanding shares of Nexus AG. By the expiration of the additional acceptance period in January 2025, TA secured 94.95% of the shares, including 26.9% previously committed by key shareholders through irrevocable undertakings. The strategic rationale for the transaction is to delist Nexus from the Frankfurt Stock Exchange (SDax) to increase operational flexibility and focus on long-term growth. TA aims to accelerate Nexus’s development through significant investments in Research & Development, specifically targeting cloud computing and AI-driven diagnostic solutions. Taking the company private allows management to pursue a more aggressive "buy-and-build" strategy through strategic acquisitions across Europe without the short-term pressures of public reporting. The settlement of the offer is expected in Q1 2025, following customary regulatory and foreign investment control clearances.

Nexus AG is a leading European provider of specialized software solutions for the healthcare market. The organization develops and distributes a comprehensive, interoperable product range including clinical information systems (Nexus / KIS) and integrated diagnostic modules. Its software covers the functional requirements of hospitals, psychiatric clinics, rehabilitation centers, and diagnostic facilities. With approximately 2,030 employees and a physical presence in nine European countries, Nexus supports customers in 71 countries globally. The company's business model is centered on digital transformation within the healthcare sector, providing high-availability platforms that improve patient outcomes and operational efficiency for healthcare providers.